The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).
Signed and dated written informed consent.
Patients aged ≥18 years on PD with RKF defined as at least 250 cc of urine output per day (assessed via 24-hour urine collection) and a minimum measured GFR of 2 ml/min/1.73m2, as measured at least once in the last 3 months.
Stable PD prescription, as determined by investigators.
Stable dose of RAAS blockade if on a medication within this class for the last 30 days.
Type 1 diabetes.
Recent (in the 30 days prior to screening) acute coronary syndrome or cerebrovascular event.
PD peritonitis within 30 days of screening.
History of organ transplant, including pancreas, pancreatic islet cells or kidney transplant.
University Health Network, Toronto
Lead sponsor